In Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals, Inc., the United States Court of Appeals for the Federal Circuit partially affirmed and partially vacated a decision by the Patent Trial and Appeal Board (PTAB) that found Bayer's asserted claims unpatentable as obvious.
